Related Experiment Videos
[Clinical evaluation of fludilat in cerebrovascular insufficiency]
Insights
Fludilat effectively treats cerebral vascular insufficiency disturbances. Clinical trials showed significant improvement with no observed side effects, unlike placebo treatments.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cerebral vascular insufficiency (CVI) significantly impacts patient health and quality of life.
- Effective pharmacological interventions for CVI symptoms are crucial for patient management.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Fludilat in patients experiencing CVI.
- To compare the outcomes of Fludilat treatment against a placebo control group.
Main Methods:
- A 3-month randomized controlled trial involving 75 patients (37 female, 38 male) aged 36-98 years.
- 50 patients received Fludilat (three tablets daily), while 25 received a placebo.
- Clinical outcomes and side effects were systematically monitored.
Main Results:
- Fludilat demonstrated high efficacy: 63.5% very good results, 20.4% good results.
- Placebo group showed significantly lower efficacy: 2.9% very good, 41.8% good results.
- No adverse side effects were reported in the Fludilat treatment group.
Conclusions:
- Fludilat is a safe and effective therapeutic option for managing symptoms associated with cerebral vascular insufficiency.
- The study supports the use of Fludilat in clinical practice for improving CVI patient outcomes.
Abstract:
In order to evaluate the clinical efficacy of Fludilat, we studied 75 patients, 37 women (49.3 per cent) and 38 men (50.7 per cent), with ages between 36 and 98 years, during a period of 3 months. 50 of the patients received Fludilat at the dose of three tablets per day during 3 months. The remaining 25 patients received Placebo during the same period of time. We obtained very good results in 63.5 per cent, good in 20.4 per cent and poor in 16.1 per cent of the patients treated with Fludilat. The results with Placebo were very good 2.9 per cent, good 41.8 per cent and poor 55.3 per cent. We observed no side effects during the treatment. Therefore from our study we conclude that Fludilat is an effective drug in the treatment of the disturbances produced by the cerebral vascular insufficiency.